The latest price target for Nephros (NASDAQ:NEPH) was reported by Benchmark on May 15, 2024. The analyst firm set a price target for $5.00 expecting NEPH to rise to within 12 months (a possible 131.65% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Nephros (NASDAQ:NEPH) was provided by Benchmark, and Nephros reiterated their speculative buy rating.

The last upgrade for Nephros Inc happened on March 8, 2024 when Benchmark raised their price target to $5. Benchmark previously had a hold for Nephros Inc.

There is no last downgrade for Nephros.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nephros, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nephros was filed on May 15, 2024 so you should expect the next rating to be made available sometime around May 15, 2025.

While ratings are subjective and will change, the latest Nephros (NEPH) rating was a reiterated with a price target of $5.00 to $5.00. The current price Nephros (NEPH) is trading at is $2.16, which is out of the analyst’s predicted range.